Abner Herrman & Brock LLC boosted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 7.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 47,696 shares of the medical research company’s stock after acquiring an additional 3,299 shares during the quarter. Amgen accounts for about 1.4% of Abner Herrman & Brock LLC’s holdings, making the stock its 29th biggest position. Abner Herrman & Brock LLC’s holdings in Amgen were worth $8,294,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Financial Advisory Service Inc. boosted its holdings in Amgen by 0.3% during the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after acquiring an additional 5 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its holdings in Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the last quarter. Ballentine Partners LLC boosted its holdings in Amgen by 0.3% during the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after acquiring an additional 9 shares during the last quarter. Hudock Capital Group LLC boosted its holdings in Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after acquiring an additional 10 shares during the last quarter. Finally, South Texas Money Management Ltd. boosted its holdings in Amgen by 0.7% during the 2nd quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock worth $555,000 after acquiring an additional 22 shares during the last quarter. 78.95% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.19% of the company’s stock.

A number of equities analysts have issued reports on AMGN shares. BMO Capital Markets reaffirmed a “market perform” rating and set a $198.00 price objective on shares of Amgen in a report on Thursday, October 26th. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday, December 2nd. Goldman Sachs Group downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Sixteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $191.84.

Shares of Amgen, Inc. (AMGN) opened at $179.52 on Thursday. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23. The stock has a market capitalization of $130,320.00, a PE ratio of 69.58, a P/E/G ratio of 2.15 and a beta of 1.42. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. During the same quarter in the prior year, the firm posted $2.89 earnings per share. The company’s revenue was down 2.7% on a year-over-year basis. equities analysts anticipate that Amgen, Inc. will post 13.22 earnings per share for the current fiscal year.

Amgen announced that its Board of Directors has initiated a share buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a $1.32 dividend. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s payout ratio is currently 178.29%.

ILLEGAL ACTIVITY WARNING: “Abner Herrman & Brock LLC Boosts Position in Amgen, Inc. (AMGN)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2018/02/15/abner-herrman-brock-llc-boosts-position-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.